|
5 Companies |
|
5 Products |
|
5 Products |
|
9 Mechanisms of Action |
|
1 Trial |
|
26 News |
|
- || Photofrin (porfimer sodium) / Advanz Pharma
Trial completion, Enrollment change, Trial completion date, Trial primary completion date: Photodynamic Therapy (PDT) for Recurrent Pediatric Brain Tumors (clinicaltrials.gov) - Feb 25, 2019
P1, N=5, Completed, Sponsor: Harry T Whelan, MD
Recruiting --> Completed | N=24 --> 5 | Trial completion date: Apr 2024 --> Jun 2018 | Trial primary completion date: Apr 2019 --> Jun 2018
- | Seprehvir (HSV1716) / Sorrento
Trial completion, Enrollment change, Trial completion date, Trial primary completion date: HSV1716 in Patients With Non-Central Nervous System (Non-CNS) Solid Tumors (clinicaltrials.gov) - Mar 21, 2018
P1, N=18, Completed, Sponsor: Timothy Cripe
Recruiting --> Completed | N=24 --> 5 | Trial completion date: Apr 2024 --> Jun 2018 | Trial primary completion date: Apr 2019 --> Jun 2018 Recruiting --> Completed | N=30 --> 18 | Trial completion date: Jul 2018 --> Mar 2018 | Trial primary completion date: Jul 2018 --> Mar 2018
- | Seprehvir (HSV1716) / Sorrento
Trial primary completion date: HSV1716 in Patients With Non-Central Nervous System (Non-CNS) Solid Tumors (clinicaltrials.gov) - Nov 18, 2017
P1, N=30, Recruiting, Sponsor: Timothy Cripe
Recruiting --> Completed | N=30 --> 18 | Trial completion date: Jul 2018 --> Mar 2018 | Trial primary completion date: Jul 2018 --> Mar 2018 Trial primary completion date: Dec 2017 --> Jul 2018
- | Trial completion, Enrollment change, Trial primary completion date: Charged Particle RT for Chordomas and Chondrosarcomas of the Base of Skull or Cervical Spine (clinicaltrials.gov) - Jun 16, 2017
P1/2, N=381, Completed, Sponsor: Massachusetts General Hospital
Trial primary completion date: Dec 2017 --> Jul 2018 Active, not recruiting --> Completed | N=274 --> 381 | Trial primary completion date: Jan 2006 --> Jul 2007
- Seprehvir (HSV1716) / Sorrento
Trial primary completion date: HSV1716 in Patients With Non-Central Nervous System (Non-CNS) Solid Tumors (clinicaltrials.gov) - Jan 31, 2017
P1, N=30, Recruiting, Sponsor: Timothy Cripe
Active, not recruiting --> Completed | N=274 --> 381 | Trial primary completion date: Jan 2006 --> Jul 2007 Trial primary completion date: Dec 2016 --> Dec 2017
- Photofrin (porfimer sodium) / Advanz Pharma
Enrollment open: Photodynamic Therapy (PDT) for Recurrent Pediatric Brain Tumors (clinicaltrials.gov) - Dec 5, 2016
P1, N=24, Recruiting, Sponsor: Harry T Whelan, MD
Trial primary completion date: Dec 2016 --> Dec 2017 Active, not recruiting --> Recruiting
- || dasatinib / Generic mfg.
Trial primary completion date, Metastases: Trial of Dasatinib in Advanced Sarcomas (clinicaltrials.gov) - Oct 13, 2016
P2, N=386, Active, not recruiting, Sponsor: Sarcoma Alliance for Research through Collaboration
Active, not recruiting --> Recruiting Trial primary completion date: Jun 2015 --> Dec 2016
- Photofrin (porfimer sodium) / Advanz Pharma
Trial primary completion date: Photodynamic Therapy (PDT) for Recurrent Pediatric Brain Tumors (clinicaltrials.gov) - Jun 1, 2016
P1, N=24, Active, not recruiting, Sponsor: Harry T Whelan, MD
Trial primary completion date: Jun 2015 --> Dec 2016 Trial primary completion date: Apr 2016 --> Apr 2019
- ||| Trial completion, Trial initiation date, Trial primary completion date: Studying Genes in Tissue Samples From Younger and Adolescent Patients With Soft Tissue Sarcomas (clinicaltrials.gov) - May 19, 2016
P=N/A, N=70, Completed, Sponsor: Children's Oncology Group
Trial primary completion date: Apr 2016 --> Apr 2019 Recruiting --> Completed | Initiation date: Mar 2012 --> May 2016 | Trial primary completion date: Jan 2100 --> May 2016
- Photofrin (porfimer sodium) / Advanz Pharma
Enrollment closed: Photodynamic Therapy (PDT) for Recurrent Pediatric Brain Tumors (clinicaltrials.gov) - Feb 12, 2016
P1, N=24, Active, not recruiting, Sponsor: Harry T Whelan, MD
Recruiting --> Completed | Initiation date: Mar 2012 --> May 2016 | Trial primary completion date: Jan 2100 --> May 2016 Recruiting --> Active, not recruiting
- Clinical data, Trial completion, Enrollment change, Trial primary completion date: CH01: Proton Therapy for Chordomas and/or Chondrosarcomas (clinicaltrials.gov) - Dec 17, 2015
P=N/A, N=189, Completed, Sponsor: University of Florida
Recruiting --> Active, not recruiting Recruiting --> Completed | N=300 --> 189 | Trial primary completion date: Jan 2022 --> Dec 2015
- Enrollment closed, Trial primary completion date: Hypoxia-positron Emission Tomography (PET) and Intensity Modulated Proton Therapy (IMPT) Dose Painting in Patients With Chordomas (clinicaltrials.gov) - Oct 6, 2015
P=N/A, N=20, Active, not recruiting, Sponsor: Massachusetts General Hospital
Recruiting --> Completed | N=300 --> 189 | Trial primary completion date: Jan 2022 --> Dec 2015 Completed --> Active, not recruiting | Trial primary completion date: Jul 2013 --> Jul 2016
- Seprehvir (HSV1716) / Sorrento
Enrollment change: HSV1716 in Patients With Non-Central Nervous System (Non-CNS) Solid Tumors (clinicaltrials.gov) - Sep 25, 2015
P1, N=30, Recruiting, Sponsor: Timothy Cripe
Completed --> Active, not recruiting | Trial primary completion date: Jul 2013 --> Jul 2016 N=18 --> 30
- ||| Enrollment open, Trial primary completion date: Studying Genes in Tissue Samples From Younger and Adolescent Patients With Soft Tissue Sarcomas (clinicaltrials.gov) - May 8, 2015
P=N/A, N=70, Recruiting, Sponsor: Children's Oncology Group
N=18 --> 30 Active, not recruiting --> Recruiting | Trial primary completion date: May 2012 --> Jan 2100
- Seprehvir (HSV1716) / Sorrento
Enrollment change, Trial primary completion date: HSV1716 in Patients With Non-Central Nervous System (Non-CNS) Solid Tumors (clinicaltrials.gov) - Feb 5, 2015
P1, N=18, Recruiting, Sponsor: Nationwide Children's Hospital
Active, not recruiting --> Recruiting | Trial primary completion date: May 2012 --> Jan 2100 N=15 --> 18 | Trial primary completion date: Aug 2014 --> Dec 2016
- ||| dasatinib / Generic mfg.
Enrollment change, Trial primary completion date, Metastases: Trial of Dasatinib in Advanced Sarcomas (clinicaltrials.gov) - Dec 19, 2014
P2, N=386, Active, not recruiting, Sponsor: Sarcoma Alliance for Research through Collaboration
N=15 --> 18 | Trial primary completion date: Aug 2014 --> Dec 2016 N=502 --> 386 | Trial primary completion date: Dec 2014 --> Jun 2015
- Trial completion: Hypoxia-positron Emission Tomography (PET) and Intensity Modulated Proton Therapy (IMPT) Dose Painting in Patients With Chordomas (clinicaltrials.gov) - Nov 7, 2014
P=N/A, N=20, Completed, Sponsor: Massachusetts General Hospital
N=502 --> 386 | Trial primary completion date: Dec 2014 --> Jun 2015 Active, not recruiting --> Completed
- || dasatinib / Generic mfg.
Trial primary completion date, Metastases: Trial of Dasatinib in Advanced Sarcomas (clinicaltrials.gov) - Jun 19, 2014
P2, N=502, Active, not recruiting, Sponsor: Sarcoma Alliance for Research through Collaboration
Active, not recruiting --> Completed Trial primary completion date: Dec 2013 --> Dec 2014
- Photofrin (porfimer sodium) / Advanz Pharma
Trial initiation date: Photodynamic Therapy (PDT) for Recurrent Pediatric Brain Tumors (clinicaltrials.gov) - Mar 24, 2013
P1, N=24, Recruiting, Sponsor: Harry T Whelan, MD
Trial primary completion date: Dec 2013 --> Dec 2014 Initiation date: Oct 2012 --> Mar 2013
- Photofrin (porfimer sodium) / Advanz Pharma
Enrollment open: Photodynamic Therapy (PDT) for Recurrent Pediatric Brain Tumors (clinicaltrials.gov) - Mar 24, 2013
P1, N=24, Recruiting, Sponsor: Harry T Whelan, MD
Initiation date: Oct 2012 --> Mar 2013 Not yet recruiting --> Recruiting
- Clinical data, Trial initiation date: CH01: Proton Therapy for Chordomas and/or Chondrosarcomas (clinicaltrials.gov) - Mar 10, 2013
P=N/A, N=300, Recruiting, Sponsor: University of Florida
Not yet recruiting --> Recruiting Initiation date: Oct 2006 --> Jan 2007
- | Photofrin (porfimer sodium) / Advanz Pharma
New P1 trial: Photodynamic Therapy (PDT) for Recurrent Pediatric Brain Tumors (clinicaltrials.gov) - Sep 9, 2012
P1, N=24, Recruiting, Sponsor: Harry T Whelan, MD
- imatinib / Generic mfg., cyclophosphamide / Generic mfg.
Trial completion: PALANGI3: Imatinib Mesylate And Cyclophosphamide In Metronomic Administration: Dose Escalation Study Of Imatinib Mesylate (clinicaltrials.gov) - Jun 5, 2012
P1, N=26, Completed, Sponsor: Centre Oscar Lambret
Initiation date: Oct 2006 --> Jan 2007 Active, not recruiting --> Completed
- Enrollment closed: Hypoxia-positron Emission Tomography (PET) and Intensity Modulated Proton Therapy (IMPT) Dose Painting in Patients With Chordomas (clinicaltrials.gov) - May 3, 2012
P=N/A, N=20, Active, not recruiting, Sponsor: Massachusetts General Hospital
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- ||| Clinical: Studying Genes in Tissue Samples From Younger and Adolescent Patients With Soft Tissue Sarcomas (clinicaltrials.gov) - Mar 26, 2012
P=N/A, N=70, Active, not recruiting, Sponsor: Children's Oncology Group